Corxel

Clinical-stage biopharma developing cardiometabolic drugs, led by CX11, an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes.

View on the globe

$287MEquity raised in 2025–20262025 — · 2026 $287M · 1 equity round
$287MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 22 Jan 2026 to 22 Jan 2026, $287M equity disclosed. Earlier rounds exist but are not sourced.22 Jan 2026: Series D1, $287M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 2019Q3Q42026Q2Q3Q4Equity round22 Jan 2026 · Series D1 · $287MSeries D · $287M
Funding history: 1 round from 22 Jan 2026 to 22 Jan 2026, $287M equity disclosed. Earlier rounds exist but are not sourced.22 Jan 2026: Series D1, $287M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’19Q3Q42026Q2Q3Q4Equity round22 Jan 2026 · Series D1 · $287M$287M

Funding history 1 round · 2 sources

Earlier rounds not yet sourced. Corxel was founded in 2019 and raised before 22 Jan 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Series D1
    Amount$287M
    Post-money—
    ✓ Confirmed
    Also
    SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital, RTW Investments, Hengdian Group Capital
    Note
    Announced as up to $287M. No lead named; RTW and Hengdian are existing investors. Founded in 2019 by RTW as Ji Xing Pharmaceuticals (BioPharma Dive). A SPAC merger with Amanat Acquisition Corp (announced 2026-10-26, with a concurrent $300M PIPE) is pending and not recorded as a venture round. Earlier rounds are not sourced here.
    Sources
  2. Earlier rounds not yet sourced

Investors 10

  • Adage Capital Management
  • HBM Healthcare Investments
  • Hengdian Group Capital
  • Invus
  • RA Capital Management
  • RTW Investments
  • SilverArc Capital
  • SR One
  • SymBiosis
  • TCG Crossover

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Corxel and its logo are trademarks of their owners, used here for identification only.